MRNA: Expecting More UpsideModerna, Inc.NASDAQ:MRNABelFed_AnalyticsModerna's recent rally is driven by two strong clinical milestones: the personalized mRNA melanoma vaccine developed with Merck hit its Phase 3 goals, and the seasonal flu shot (mFLUSIVA) received FDA approval. Analysts are treating the melanoma result as a landmark validation of Moderna's oncology pipeline, and price targets have been revised sharply higher. The technical picture confirms the fundamental story. The broader trend structure supports further upside expansion toward the 250–310 resistance zone over the coming months. Chart: We keep this scenario active as long as price holds above the 117–103 support area. We plan to enter once a clean risk/reward setup appears.